When Kenneth Frazier became CEO of Merck & Co. in 2011, he knew from the outset that consideration of all the company's stakeholders — customers, investors, employees, and society at large ...

In Phase II studies, Merck showed that it had a cure rate of 98%. The study also brought on a 94% cure rate in another group. How this pans out in larger studies may not be known until 2015.